There are currently 196 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
NCT05535244
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Mayo Clinic - Arizona, Phoenix, Arizona +32 locations
Conditions: Multiple Myeloma
Register for Updates
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
NCT05776979
Recruiting
To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/28/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Multiple Myeloma
Register for Updates
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
NCT05646576
Recruiting
The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups. The names of the study intervention groups involved in this study are: Palliative care (PEACE) plus usual oncology care Usual care (standard on... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Hematologic Malignancy, Blood Cancer, Lymphoma, Leukemia, Multiple Myeloma
Register for Updates
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623
Recruiting
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: GSK Investigational Site, Tucson, Arizona +129 locations
Conditions: Multiple Myeloma
Register for Updates
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab
NCT05053607
Recruiting
This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data. Fifty adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc will be enrolled across 2 sites, The University of California San Francisco and The University of Texas MD Anderson Cancer Center. Consented participants will be enrolled in a 3-m... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas +1 locations
Conditions: Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843
Recruiting
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +18 locations
Conditions: Multiple Myeloma
Register for Updates
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
NCT05956457
Recruiting
This study will evaluate the feasibility of a digital health coaching program for adults with relapsed or refractory multiple myeloma (R/R MM). One hundred adults with R/R MM will be enrolled at The University of Washington. Individuals who agree to take part in the study and sign an informed consent will be enrolled in a 3-month digital health coaching program. The program will provide weekly phone calls plus the delivery of learning materials to text or email. Questionnaires and data from a wr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: University of Washington, Seattle, Washington
Conditions: Multiple Myeloma, Relapsed Hematologic Malignancy
Register for Updates
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
NCT04398745
Recruiting
Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at risk or already has renal dysfunction at initial diagnosis. The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in participants with RRMM, who have had at least 3 lin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: GSK Investigational Site, Tucson, Arizona +25 locations
Conditions: Multiple Myeloma
Register for Updates
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT05969860
Recruiting
This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Currently most drug-related cancer care is conducted in infusion centers or specialty hospitals, where patients spend many hours a day isolated from family, friends, and familiar surroundings. This separation adds to the physical, emotional, social, and... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Advanced Malignant Solid Neoplasm, Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma, Advanced Carcinoid Tumor, Advanced Cervical Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastric Carcinoma, Advanced Glioblastoma, Advanced Head and Neck Carcinoma, Advanced HER2 Positive Breast Carcinoma, Advanced Lung Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Germ Cell Tumor, Advanced Neuroendocrine Carcinoma, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Prostate Small Cell Neuroendocrine Carcinoma, Hematopoietic and Lymphoid System Neoplasm, Multiple Myeloma, Myelodysplastic Syndrome
Register for Updates
DARA RVD For High Risk SMM
NCT04775550
Recruiting
The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to active or symptomatic multiple myeloma. The names of the study drugs involved in this study are: Daratumumab (also called Darzalex Faspro) Bortezomib (also called Velcade) Lenalidomide (also called Revlimid) Dexamethasone
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +4 locations
Conditions: High-risk Smoldering Multiple Myeloma, Multiple Myeloma
Register for Updates
64Cu-LLP2A for Imaging Multiple Myeloma
NCT03804424
Recruiting
The investigators are performing a trial with goals to demonstrate the feasibility of imaging multiple myeloma (MM) patients with 64Cu-LLP2A-positron emission tomography (PET)/magnetic resonance (MR). The investigators suggest that 64Cu-LLP2A will allow for an accurate molecular imaging of MM lesions, which will have an important impact on early stage disease detection and in the long term on the initiation and choice of therapy in these patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Multiple Myeloma
Register for Updates
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
NCT04091126
Recruiting
This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination of bortezomib, lenalidomide and dexamethasone (VRd) on a 3-week cycle until cycle 8, followed by the combination of lenalidomide and d... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: GSK Investigational Site, Yuma, Arizona +40 locations
Conditions: Multiple Myeloma
Register for Updates